Skip to main content
. Author manuscript; available in PMC: 2024 Jan 10.
Published in final edited form as: N Engl J Med. 2020 Aug 27;383(9):825–835. doi: 10.1056/NEJMoa2005651

Figure 2:

Figure 2:

Kaplan-Meier plots of (A) duration of response among 34 patients with a response and (B) progression-free survival in all 55 patients in the vandetanib and/or cabozantinib pretreated RET-mutant MTC group according to investigator assessments.